These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 27550361)

  • 1. Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.
    Furin JJ; Du Bois J; van Brakel E; Chheng P; Venter A; Peloquin CA; Alsultan A; Thiel BA; Debanne SM; Boom WH; Diacon AH; Johnson JL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6591-6599. PubMed ID: 27550361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.
    Botha FJ; Sirgel FA; Parkin DP; van de Wal BW; Donald PR; Mitchison DA
    S Afr Med J; 1996 Feb; 86(2):155-8. PubMed ID: 8619142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
    Diacon AH; De Jager VR; Dawson R; Narunsky K; Vanker N; Burger DA; Everitt D; Pappas F; Nedelman J; Mendel CM
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of time to positive and colony counting in an early bactericidal activity study of anti-tuberculosis treatment.
    Bark CM; Gitta P; Ogwang S; Nsereko M; Thiel BA; Boom WH; Eisenach KD; Joloba ML; Johnson JL
    Int J Tuberc Lung Dis; 2013 Nov; 17(11):1448-51. PubMed ID: 24125449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis.
    Chan SL; Yew WW; Ma WK; Girling DJ; Aber VR; Felmingham D; Allen BW; Mitchison DA
    Tuber Lung Dis; 1992 Feb; 73(1):33-8. PubMed ID: 1326348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis.
    Dietze R; Hadad DJ; McGee B; Molino LP; Maciel EL; Peloquin CA; Johnson DF; Debanne SM; Eisenach K; Boom WH; Palaci M; Johnson JL
    Am J Respir Crit Care Med; 2008 Dec; 178(11):1180-5. PubMed ID: 18787216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies.
    De Jager V; van der Merwe L; Venter A; Donald PR; Diacon AH
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis.
    Kim JS; Kim YH; Lee SH; Kim YH; Kim JW; Kang JY; Kim SK; Kim SJ; Kang YS; Kim TH; Mok J; Byun MK; Park HJ; Joh JS; Park YB; Lim HS; Choi H; Lee SH; Kim H; Yang J; Kim H; Shen X; Alsultan A; Cho I; Geiter L; Shim TS
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0168421. PubMed ID: 34871098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment.
    McAulay K; Saito K; Warrier T; Walsh KF; Mathurin LD; Royal-Mardi G; Lee MH; Ocheretina O; Pape JW; Fitzgerald DW; Nathan CF
    mBio; 2018 Nov; 9(6):. PubMed ID: 30459198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II dose-ranging trial of the early bactericidal activity of PA-824.
    Diacon AH; Dawson R; du Bois J; Narunsky K; Venter A; Donald PR; van Niekerk C; Erondu N; Ginsberg AM; Becker P; Spigelman MK
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3027-31. PubMed ID: 22430968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.
    Diacon AH; Dawson R; Hanekom M; Narunsky K; Maritz SJ; Venter A; Donald PR; van Niekerk C; Whitney K; Rouse DJ; Laurenzi MW; Ginsberg AM; Spigelman MK
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3402-7. PubMed ID: 20498324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.
    Donald PR; Sirgel FA; Botha FJ; Seifart HI; Parkin DP; Vandenplas ML; Van de Wal BW; Maritz JS; Mitchison DA
    Am J Respir Crit Care Med; 1997 Sep; 156(3 Pt 1):895-900. PubMed ID: 9310010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment.
    Sirgel FA; Botha FJ; Parkin DP; Van De Wal BW; Donald PR; Clark PK; Mitchison DA
    J Antimicrob Chemother; 1993 Dec; 32(6):867-75. PubMed ID: 8144427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
    Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
    PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.
    Gillespie SH; Gosling RD; Uiso L; Sam NE; Kanduma EG; McHugh TD
    J Antimicrob Chemother; 2005 Dec; 56(6):1169-71. PubMed ID: 16223939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis.
    Wallis RS; Dawson R; Friedrich SO; Venter A; Paige D; Zhu T; Silvia A; Gobey J; Ellery C; Zhang Y; Eisenach K; Miller P; Diacon AH
    PLoS One; 2014; 9(4):e94462. PubMed ID: 24732289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
    Conde MB; Efron A; Loredo C; De Souza GR; Graça NP; Cezar MC; Ram M; Chaudhary MA; Bishai WR; Kritski AL; Chaisson RE
    Lancet; 2009 Apr; 373(9670):1183-9. PubMed ID: 19345831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group.
    Hafner R; Cohn JA; Wright DJ; Dunlap NE; Egorin MJ; Enama ME; Muth K; Peloquin CA; Mor N; Heifets LB
    Am J Respir Crit Care Med; 1997 Sep; 156(3 Pt 1):918-23. PubMed ID: 9310014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early bactericidal action of pulsed exposure to rifampicin, ethambutol, isoniazid & pyrazinamide in pulmonary tuberculosis patients.
    Paramasivan CN; Herbert D; Umapathy KC; Rahman F; Krishnamurthy PV; Prabhakar R
    Indian J Med Res; 1994 Jul; 100():1-4. PubMed ID: 7927544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.